WebAlthough an ongoing phase 3b–4 study (CheckMate 511; ClinicalTrials.gov number, NCT02714218) is evaluating the safety profile of nivolumab at a dose of 3 mg per kilogram plus ipilimumab at a... WebMay 4, 2024 · The randomized Checkmate-511 study compared nivolumab with ipilimumab at 1 mg/kg or 3 mg/kg, demonstrating that high-grade adverse events (grades 3-5) occurred in 34% versus 48% of patients, respectively, whereas exploratory efficacy outcomes were similar. 7 No prospective studies have yet described the utility of anti-PD-1 plus anti …
CONSORT diagram. Patient disposition as of June 1, 2024.
WebAnalysis of the phase 3b/4 CheckMate 511 study (NCT02714218) at 1 y showed that NIVO 3 mg/kg plus IPI 1 mg/kg (NIVO3 + IPI1) improves the safety profile of the combination; efficacy with the 2 regimens was similar in descriptive analyses. Here we present 3-y safety/efficacy results. WebFeb 27, 2024 · The CheckMate 511 study met its primary end point, demonstrating a significantly lower incidence of treatment-related grade 3 to 5 AEs with NIVO3+IPI1 … hwy is atss named that
National Center for Biotechnology Information
WebOct 8, 2024 · Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial Article Full-text available... WebDec 8, 2024 · The randomized CheckMate-511 trial compared the standard dosing of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg versus the opposite—nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, followed by nivolumab 480 mg once every 4 weeks—in patients with advanced melanoma. 4 The flipped dosing strategy was associated with a significantly … WebJun 23, 2024 · Jason alluded to the CheckMate 511 study, which was comparing alternate dosing of 3 mg and 1 mg ipilimumab-nivolumab versus 1 mg and 3 mg ipilimumab-nivolumab times 4 doses and then maintenance ... hwy in texting